TCB-002 is under clinical development by TC BioPharm and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to GlobalData, Phase II drugs for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TCB-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TCB-002 overview
TCB-002 (OmnImmune) is under development for the treatment of relapsed or refractory acute myeloid leukaemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia (CLL) and multiple myeloma, myelodysplastic syndrome, chronic myelomonocytic leukemia (CMML), myeloproliferative neoplasms and ovarian cancer. The therapeutic candidate comprises of allogeneic unmodified CD3 positive T lymphocytes expressing the Vgamma9Vdelta2 T-cell receptor. It is administered through intravenous route and is being developed based on CryoTC technology.
See Also:
OmnImmune was also under development for Epstein Barr associated pneumonia.
TC BioPharm overview
TC BioPharm is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products. The company’s pipeline products include OmnImmune. OmnImmune is used for the treatment of Acute Myeloid Leukaemia (AML). The company offers clinical trials, clinical development among others.. TC BioPharm therapies focuses on leveraging the inherent biological capabilities of gamma delta T cells (GDT cells). It works in collaboration with various cancer centers in Glasgow, Edinburgh and Southampton to develop ImmuniCell, among others. The company provides clinical manufacturing facility which is located in Holytown, Scotland, the UK. TC BioPharm is headquartered in Glasgow, Scotland, United Kingdom.
For a complete picture of TCB-002’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
